Top Markets
#1 ORDI ORDI +105.28%
#2 pippin pippin +48.89%
#3 tomiNet tomiNet +42.76%
#4 SATS (Ordinals) SATS (Ordinals) +41.44%
#5 1000SATS (Ordinals) 1000SATS (Ordinals) +40.63%
#6 Axelar Axelar +28.30%
#7 Bio Protocol Bio Protocol +27.90%
#8 Swarms Swarms +26.30%
#9 Drift Protocol Drift Protocol +25.62%
#10 MemeCore MemeCore +24.82%
Coin of the day
ORDI ORDI
Settings
Language
ENGLISH
Currency
USD
Theme
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rank in Stocks #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Share Price
$0.00047446
Market Cap
$82.80
Change (1 day)
0.00%
Change (1 year)
-98.16%
Country
FR
Trade Neovacs S.A. (ALNEV)

Category

Healthcare
Revenue for Neovacs S.A. (ALNEV)
Revenue in Dec 2024 TTM: $303.12K
According to Neovacs S.A. latest financial reports the company's current revenue (TTM) is $303.12K. In 2023 the company made a revenue of $589.67K an increase over the revenue in the year 2022 that was $1.19K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Neovacs S.A. from 2007 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $303.12K -20.48%
2024 $381.21K -35.35%
2023 $589.67K 49,335.08%
2022 $1.19K -95.36%
2021 $25.69K -29.17%
2020 $36.27K 0.00%
2019 0.00 -100.00%
2018 $166.63K 0.00%
2017 0.00 -100.00%
2016 $16.23K -89.89%
2015 $160.58K -6.42%
2014 $171.60K 317.73%
2013 $41.08K 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 -100.00%
2008 $75.78K -59.14%
2007 $185.43K 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.55B 16,015,729.38%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 3,971,340.03%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 4,731,589.19%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 2,996,119.45%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 1,811,461.99%
NL